Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582553 · ClinicalTrials.gov registry record · Early Phase 1
Safety and Pharmacokinetics of an Extract of Naringenin
A Early Phase 1 study, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03582553 is a Early Phase 1 study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 18 participants.
The verdict
NCT03582553, a Early Phase 1 study, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study evaluates the safety of administering single ascending doses (150, 300, 600, and 900 mg) of a citrus extract of the flavonoid narigenin, and assesses the blood concentrations of naringenin following oral administration of the extract.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Naringenin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-25 |
| Est. Completion | 2018-09-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03582553
The ClinicalTrials.gov registry entry for NCT03582553 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03582553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03582553 about?
NCT03582553 is a clinical study titled "Safety and Pharmacokinetics of an Extract of Naringenin". This study evaluates the safety of administering single ascending doses (150, 300, 600, and 900 mg) of a citrus extract of the flavonoid narigenin, and assesses the blood concentrations of naringenin following oral administration of the extract.
What is the current status of trial NCT03582553?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2018-05-25. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT03582553?
The interventions under investigation include: Placebo (OTHER), Naringenin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03582553?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.